• Agreement takes Gene Editing to Japanese Pharma

News & Views

Agreement takes Gene Editing to Japanese Pharma

Feb 25 2020

A licensing agreement between Daiichi Sankyo and ERS Genomics provides the Japanese pharmaceutical company with access to foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, for use in its internal research and development to address areas of unmet medical need.

Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”

The Dublin-based company holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic.


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events